ATE366939T1 - Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen - Google Patents

Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen

Info

Publication number
ATE366939T1
ATE366939T1 AT01945050T AT01945050T ATE366939T1 AT E366939 T1 ATE366939 T1 AT E366939T1 AT 01945050 T AT01945050 T AT 01945050T AT 01945050 T AT01945050 T AT 01945050T AT E366939 T1 ATE366939 T1 AT E366939T1
Authority
AT
Austria
Prior art keywords
liver fibrosis
diagnosis
serum marker
timp
mmp
Prior art date
Application number
AT01945050T
Other languages
English (en)
Inventor
Michael Voelker
Michael Becka
Werner Kroll
Andreas Knorr
Sylvia Unger
Mathias Gehrmann
Guido Hennig
Elmar-Reinhold Burchardt
Michael Arthur
Alastair Burt
Massimo Pinzani
Detlef Schuppan
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00109063A external-priority patent/EP1150123B1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of ATE366939T1 publication Critical patent/ATE366939T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
AT01945050T 2000-04-28 2001-04-26 Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen ATE366939T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109063A EP1150123B1 (de) 2000-04-28 2000-04-28 Diagnose von Leberfibrose mit Hilfe von Serummarkeralgorithmen
IT2001MI000813A ITMI20010813A1 (it) 2000-04-28 2001-04-13 Valutazione di fibrosi del fegato con algoritmi basati su marcatori del siero

Publications (1)

Publication Number Publication Date
ATE366939T1 true ATE366939T1 (de) 2007-08-15

Family

ID=29713312

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01945050T ATE366939T1 (de) 2000-04-28 2001-04-26 Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen

Country Status (7)

Country Link
US (1) US7141380B2 (de)
EP (1) EP1283989B1 (de)
AT (1) ATE366939T1 (de)
AU (1) AU6738001A (de)
DE (1) DE60129314T2 (de)
ES (1) ES2288962T3 (de)
WO (1) WO2001086304A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7668661B2 (en) * 2000-04-28 2010-02-23 Siemens Healthcare Diagnostics Inc. Liver disease-related methods and systems
US6631330B1 (en) 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
AU2003300407A1 (en) * 2002-12-24 2004-07-22 Biosite Incorporated Method and system for disease detection using marker combinations
ATE462001T1 (de) * 2002-12-24 2010-04-15 Nitto Boseki Co Ltd Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
US7670764B2 (en) 2003-10-24 2010-03-02 Prometheus Laboratories Inc. Methods of diagnosing tissue fibrosis
FR2870348B1 (fr) * 2004-05-14 2010-08-27 Univ Angers Methode pour diagnostiquer la presence et/ou la severite d'une pathologie hepathique chez un sujet
EP1626280B1 (de) * 2004-08-12 2007-02-14 Roche Diagnostics GmbH Verfahren zur Diagnose von Leberfibrose.
US7809170B2 (en) * 2006-08-10 2010-10-05 Louisiana Tech University Foundation, Inc. Method and apparatus for choosing and evaluating sample size for biometric training process
KR100999720B1 (ko) 2008-11-13 2010-12-08 아주대학교산학협력단 간 경변 진단을 위한 분석방법
CN102301237B (zh) * 2008-12-02 2014-05-14 财团法人工业技术研究院 用于肝纤维化诊断的生物标记
KR101018960B1 (ko) 2009-02-23 2011-03-02 아주대학교산학협력단 유의성있는 간섬유화 진단을 위한 분석 방법
CN102334122B (zh) 2009-02-26 2018-04-27 昂热大学 肝纤维化或肝硬化的改进诊断
BRPI1009461B1 (pt) 2009-03-19 2019-08-20 Universite D'angers Métodos não invasivo para avaliar a progressão da fibrose hepática em um indivíduo e para avaliar se o indivíduo é formador de fibrose lenta, média ou rápida
CN102020715B (zh) * 2010-10-22 2012-09-05 上海贝西生物科技有限公司 一种抗ⅲ型前胶原氨基末端肽单克隆抗体及其用途
EP2684513A1 (de) * 2012-07-13 2014-01-15 Universite D'angers Verfahren zur Bereitstellung zuverlässiger, nichtinvasiver Diagnosetests
FR3023003B1 (fr) 2014-06-27 2016-07-15 Bio-Rad Innovations Combinaison synergique de biomarqueurs pour la detection et l'evaluation d'une fibrose hepatique
EP3491388B1 (de) 2016-08-01 2021-09-01 Centre Hospitalier Universitaire d'Angers Multi-zielgerichteten fibrosetests
PL425251A1 (pl) * 2018-04-17 2019-10-21 Uniwersytet Kazimierza Wielkiego Panel analityczny jako jeden z elementów wieloaspektowego procesu ustalającego stan zdrowia, dysfunkcji wątroby dla osób z zespołem zależności alkoholowej
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
CN119032274A (zh) * 2022-04-20 2024-11-26 美国西门子医学诊断股份有限公司 特发性肺纤维化生物标志物及其生产和使用方法
ES2957479B2 (es) * 2022-06-07 2025-07-28 Baigene S L Metodo de obtencion de datos utiles para la prediccion del riesgo de un sujeto de sufrir fibrosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060255A (en) * 1997-10-03 2000-05-09 Tosoh Corporation Type IV collagen high molecular form and production and diagnostic use thereof

Also Published As

Publication number Publication date
EP1283989B1 (de) 2007-07-11
DE60129314T2 (de) 2008-07-17
WO2001086304A3 (en) 2002-04-04
EP1283989A2 (de) 2003-02-19
DE60129314D1 (de) 2007-08-23
WO2001086304A2 (en) 2001-11-15
ES2288962T3 (es) 2008-02-01
AU6738001A (en) 2001-11-20
US20040053242A1 (en) 2004-03-18
US7141380B2 (en) 2006-11-28

Similar Documents

Publication Publication Date Title
ATE366939T1 (de) Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen
de Bock et al. Clinical significance of urokinase‐type plasminogen activator receptor (uPAR) expression in cancer
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
ATE331960T1 (de) Diagnose von myokardinfarkt und akutem koronarsyndrom durch kombination von markern
EP1616184A4 (de) Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
EP1116029A4 (de) Antikörper für apoptosemarker und anwendungsverfahren
ATE489633T1 (de) Verfahren zum frühzeitigen nachweis herzerkrankungen
DE60321552D1 (de) Neues verfahren für die diagnose und prognose von malignen erkrankungen
DE60117592D1 (de) Diagnose von pre-eclampsia
ATE395812T1 (de) Methoden zur vorhersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
EP1130401A3 (de) Assays zur Bestimmung von Typ-II-Kollagenfragmenten in Harn
CN101142483A (zh) 以鳞状上皮细胞癌抗原为指标的皮肤性状的评价方法
DE69821246D1 (de) Testverfahren für collagenpeptid
DE10082504D2 (de) Indikatorpeptid zur Diagnose und/oder Vorhersage von cardiovasculären und /oder endothelialen Erkrankungen, Antikörperzusammensetzung und immunoassay
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
FR2795823B1 (fr) Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
ATE271225T1 (de) Verwendung von urintrypsininhibitor zur diagnose von aids
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
CA2524708A1 (en) Use of protein cellular retinoic acid-binding protein ii (crabp ii) as marker for breast cancer
DE60225168D1 (de) Verfahren zur auswahl bioaktiver wirkstoffe durch lumineszenzkopplung und lebendes zellensystem dafür
CA2358504A1 (en) Methods of determining an increased risk of a woman carrying a downs syndrome affected fetus by measuring an analyte in a biological sample
DE602005010548D1 (de) Verbessertes verfahren zur diagnose des akuten koronarsyndroms
ATE437368T1 (de) Verfahren zum prüfen von mit wt1-verbundenen krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties